trending Market Intelligence /marketintelligence/en/news-insights/trending/drhjngv8djuwtskmuf7ahw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Matinas BioPharma appoints vice chairman

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Matinas BioPharma appoints vice chairman

Matinas BioPharma Holdings Inc. appointed Patrick LePore as vice chairman of the board.

LePore served as the CEO, chairman and president of Par Pharmaceuticals Inc. from 2006 to 2012.

Matinas Biopharma said in a Sept. 6 news release that Lepore oversaw the sale of Par Pharmaceuticals to Texas Pacific Group for $2 billion in November 2012 and was appointed as the chairman. He oversaw the new company's $8 billion sale to Endo International PLC in 2015.

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications.